Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2016-08-16 Regulatory Filings
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2016
Regulatory Filings
2016-08-16 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release titled 'RedHill Biopharma Provides 2016 Semi-Annual R&D Update'. Form 6-K is used by foreign private issuers to report material information that is not required to be filed on Forms 20-F or 40-F. The document is short (1866 characters) and primarily serves as a regulatory filing to disclose a press release rather than a full financial report or detailed analysis. It does not contain comprehensive financial statements or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2016-08-11 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. Form 6-K is used by foreign private issuers to report material information that is not required to be filed on Forms 20-F or 40-F. The content includes a press release about a clinical study milestone, not a full financial report or detailed financial data. The document length is short (1912 characters), and it primarily serves as a regulatory announcement of a press release rather than a comprehensive report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2016-08-01 English
6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release and condensed interim unaudited financial information for the six and three months ended June 30, 2016. Form 6-K filings typically provide interim or quarterly financial updates for foreign private issuers. The document contains actual financial data for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. The document length is 2133 characters, which is relatively short but contains substantive financial information, not just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2016-07-26 English
FORM 6-K
Regulatory Filings Classification · 100% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It contains a press release about receiving an additional U.S. patent and references incorporation by reference into registration statements. The document is short (1936 characters) and primarily serves as a regulatory update rather than a full financial report or detailed filing. Form 6-K filings are typically considered Regulatory Filings (RNS) as they provide miscellaneous updates and disclosures by foreign private issuers that do not fit into other specific categories. There is no detailed financial data, management discussion, or other report content present. Therefore, the appropriate classification is Regulatory Filings (RNS).
2016-07-21 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, RedHill Biopharma Ltd., submitted to the SEC. It references a press release about hosting a second quarter 2016 financial results conference call. The document itself is short (1902 characters) and primarily serves to announce the upcoming earnings call rather than providing detailed financial data or the call transcript itself. Form 6-K filings are typically used for current reports by foreign private issuers and often include announcements or press releases. Since this document announces the conference call but does not contain the transcript or detailed financial results, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2016-07-19 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.